Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients
Authors: Nina Singh, Marilyn M. Wagener
Journal: Annals of Internal Medicine (2006)

Letters21 March 2006Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant RecipientsNina Singh, MD and Marilyn M. Wagener, MPHNina Singh, MDFrom the University of Pittsburgh and VA Medical Center, Pittsburgh, PA 15240. and Marilyn M. Wagener, MPHFrom the University of Pittsburgh and VA Medical Center, Pittsburgh, PA 15240.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-6-200603210-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The meta-analysis by Kalil and colleagues (1) examining universal prophylaxis and preemptive therapy for cytomegalovirus (CMV) organ disease addresses an important issue. However, the conclusions may be potentially misleading because of significant limitations of the included studies, variability in the duration of prophylaxis and the length of follow-up in the published studies, and the selection of trials for the meta-analysis. The studies by Conti (2) and Hibberd (3) and colleagues cannot truly be considered to examine preemptive therapy. Prophylactic use of an antiviral agent in patients receiving antilymphocytic antibodies was based on the likelihood of CMV infection ...References1. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143:870-80. [PMID: 16365468] LinkGoogle Scholar2. Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg. 1995;130:1217-21. [PMID: 7487465] CrossrefMedlineGoogle Scholar3. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized, controlled trial. Ann Intern Med. 1995;123:18-26. [PMID: 7762909] LinkGoogle Scholar4. Rayes N, Seehofer D, Schmidt CA, Oettle H, Muller AR, Steinmuller T, et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation. 2001;72:881-5. [PMID: 11571454] CrossrefMedlineGoogle Scholar5. Sagedal S, Nordal KP, Hartmann A, Midtvedt K, Foss A, Asberg A, et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant. 2003;18:1899-908. [PMID: 12937241] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Nina Singh, MD; Marilyn M. Wagener, MPHAffiliations: From the University of Pittsburgh and VA Medical Center, Pittsburgh, PA 15240.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPreemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients Patricia L. Hibberd , Nina E. Tolkoff-Rubin , David Conti , Frank Stuart , J. Richard Thistlethwaite , John F. Neylan , David R. Snydman , Richard Freeman , Marc I. Lorber , and Robert H. Rubin Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients Andre C. Kalil , Josh Levitsky , Elizabeth Lyden , Julie Stoner , and Alison G. Freifeld Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients Andre C. Kalil and Julie Stoner Metrics Cited byHuman Cytomegalovirus Is Associated with Lower HCC Recurrence in Liver Transplant PatientsPlasma cytomegalovirus DNA load predicts outcomes in liver transplant recipientsCytomegalovirus infection after liver transplantationManagement of cytomegalovirus infection and disease in liver transplant recipientsCytomegalovirus Infection in Liver Transplant RecipientsCytomegalovirus antivirals and development of improved animal modelsCurrent concepts on cytomegalovirus infection after liver transplantationIntrahepatic Cholestasis After Liver TransplantationCytomegalovirus infection after liver transplantation: Current concepts and challengesCytomegalovirus Prevention: Prophylaxis and Preemptive TherapyLe greffé hépatique face au risque infectieux 21 March 2006Volume 144, Issue 6Page: 456-457KeywordsAntiviral therapyAntiviralsConflicts of interestCytomegalovirus infectionOpportunistic infectionsProphylaxisViral replicationViremia ePublished: 21 March 2006 Issue Published: 21 March 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...